Bioequivalence Study of Clindamycin Phosphate Topical Lotion, 1% in Subjects With Acne Vulgaris
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of GDC 268 and Clindamycin Phosphate Topical Lotion, 1% in Subjects With Acne Vulgaris
Sponsor: Balmoral Medical company
Listed as NCT03717506, this PHASE3 trial focuses on Acne Vulgaris and remains completed. Sponsored by Balmoral Medical company, it has been updated 12 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Dec 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2023 — Dec 2023 [monthly]
Completed PHASE3
▶ Show 7 earlier versions
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE3
-
Jun 2021 — Dec 2022 [monthly]
Completed PHASE3
-
Jan 2021 — Jun 2021 [monthly]
Completed PHASE3
-
Aug 2020 — Jan 2021 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Feb 2020 — Aug 2020 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Dec 2018 — Feb 2020 [monthly]
Recruiting PHASE3
-
Nov 2018 — Dec 2018 [monthly]
Recruiting PHASE3
First recorded
Oct 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Balmoral Medical company
For direct contact, visit the study record on ClinicalTrials.gov .